Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Streptococcal Infection Clear all
Active, not recruiting No phase listed Observational

Reducing Antibiotic Use by Implementation of Stewardship in Primary and Urgent Care

NCT07217002
View directory record Official record
Conditions
Community Acquired Pneumonia (CAP), Sinusitis, Strep Pharyngitis, Acute Otitis Media (AOM)
Interventions
Online Educational Modules, Prescribing Feedback Reports, Clinical Decision Support, Live, hybrid in-person and online educational sessions
Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
6 Months to 12 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study Comparing a 13-valent Pneumococcal Conjugate Vaccine With 23-valent Pneumococcal Polysaccharide Vaccine in Adults

NCT00427895
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
13-valent pneumococcal conjugate vaccine (13vPnC), 23-valent Pneumococcal Polysaccharide Vaccine (23vPS)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
2,141 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
26
States / cities
Huntsville, Alabama • Chandler, Arizona • Phoenix, Arizona + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2021 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)

NCT03480802
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
4
States / cities
Orlando, Florida • West Palm Beach, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, Immunogenicity, and Lot Consistency of V116 in Adults 18 to 49 Years of Age (V116-004, STRIDE-4)

NCT05464420
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
V116, PPSV23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
2,162 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
30
States / cities
Mesa, Arizona • Tempe, Arizona • Little Rock, Arkansas + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 1 Interventional

A Double-Blind Placebo-Controlled Trial of the Safety and Immunogenicity of a Seven Valent Pneumococcal Conjugate Vaccine in Presumed HIV-Infected Infants

NCT00000829
View directory record Official record
Conditions
HIV Infections, Pneumococcal Infections
Interventions
Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Months to 6 Months
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1999
U.S. locations
31
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 21 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Children

NCT06531538
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
12 Months to 15 Months
Enrollment
225 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
35
States / cities
Washington D.C., District of Columbia • Miami, Florida • Chamblee, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Integrated Outpatient Treatment of Opioid Use Disorder and Severe Injection Related Infections

NCT04677114
View directory record Official record
Conditions
Drug Use, Opioid-use Disorder
Interventions
Buprenorphine and Outpatient Parenteral Antibiotic Therapy, Buprenorphine and standard of care antibiotic treatment
Drug
Lead sponsor
Laura Fanucchi
Other
Eligibility
18 Years to 99 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evidence Based Decision Making: Integrating Clinical Prediction Rules

NCT01386047
View directory record Official record
Conditions
Strep Pharyngitis, Pneumonia
Interventions
Integrated Clinical Prediction Rule (iCPR)
Other
Lead sponsor
Northwell Health
Other
Eligibility
Not listed
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2012 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants

NCT05844423
View directory record Official record
Conditions
Pneumococcal Vaccines
Interventions
0.5 ml dose of 1.1 mcg VAX-24, 0.5 ml dose of PCV20, 0.5 ml dose of 2.2 mcg VAX-24, 0.5 ml dose of 2.2/4.4 mcg VAX-24
Biological
Lead sponsor
Vaxcyte, Inc.
Industry
Eligibility
42 Days to 89 Days
Enrollment
802 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
32
States / cities
Jonesboro, Arkansas • Madera, California • Tampa, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2025 · Synced Sep 28, 2026, 9:53 PM EDT
Completed No phase listed Observational

Curian S. Pneumo/Legionella Assay Beta Clinical Trial Protocol

NCT05681156
View directory record Official record
Conditions
Streptococcus Pneumoniae Infection, Legionella Pneumophila Serogroup 1 Infection
Interventions
N/A- There is no intervention.
Other
Lead sponsor
Meridian Bioscience, Inc.
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 28, 2025 · Synced Sep 28, 2026, 9:53 PM EDT
Recruiting Phase 3 Interventional Accepts healthy volunteers

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants.

NCT07629440
View directory record Official record
Conditions
Pneumococcal Disease
Interventions
PG4, 20-valent pneumococcal conjugate vaccine (20vPnC)
Biological
Lead sponsor
Pfizer
Industry
Eligibility
42 Days to 211 Days
Enrollment
3,230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
106
States / cities
Bessemer, Alabama • Birmingham, Alabama • Centreville, Alabama + 75 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

Efficacy, Safety, and Tolerability of TD1414 2% Cream in Impetigo and Secondarily Infected Traumatic Lesions (SITL)

NCT00626795
View directory record Official record
Conditions
Impetigo, Secondarily Infected Traumatic Lesions
Interventions
TD1414 2% cream, Bactroban® (mupirocin) 2% cream
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
2 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Anniston, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Not applicable Interventional

Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs

NCT00013871
View directory record Official record
Conditions
HIV Infections, Hepatitis B, Measles, Pneumococcal Infections, Pertussis
Interventions
Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed, Measles-Mumps-Rubella Vaccine (Live), Pneumococcal Vaccine, Polyvalent (23-valent), Pneumococcal Conjugate Vaccine, Heptavalent, Hepatitis B Vaccine (Recombinant)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 18 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2004
U.S. locations
38
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 9:53 PM EDT
Completed No phase listed Observational

Pilot Study of Strepic® Device for the Diagnosis of Group A Streptococcal Pharyngitis

NCT03777098
View directory record Official record
Conditions
Group A Streptococcal Infection
Interventions
Strepic® Device
Device
Lead sponsor
David A. Talan
Other
Eligibility
7 Years to 64 Years
Enrollment
426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Sylmar, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2022 · Synced Sep 28, 2026, 9:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Rapid Diagnostic Test for Detection of Group B Streptococcus in Pregnancy

NCT01445717
View directory record Official record
Conditions
Streptococcus Infection, Pregnancy
Interventions
Not listed
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
358 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 2, 2013 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Phase 1/Phase 2 Study of Polyvalent Pneumococcal Conjugate Vaccine (V116) in Adults (V116-001)

NCT04168190
View directory record Official record
Conditions
Pneumonia, Pneumococcal
Interventions
V116, Pneumovax™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
20
States / cities
Birmingham, Alabama • Mesa, Arizona • Coral Gables, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2022 · Synced Sep 28, 2026, 9:53 PM EDT
Suspended Not applicable Interventional

CandyCollect Strep Throat Testing

NCT05175196
View directory record Official record
Conditions
Group A Streptococcal Infection
Interventions
CandyCollect, Lollipop Swab
Diagnostic Test
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
5 Years to 17 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Sep 28, 2026, 9:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Rapid Strep Test Results

NCT04256694
View directory record Official record
Conditions
Strept Throat
Interventions
Rapid Antigen Test for Group A Streptococcus
Diagnostic Test
Lead sponsor
Kendall Healthcare Group, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 2, 2020 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Immune Response to Pneumococcal Vaccination in HIV Infected Individuals

NCT02515240
View directory record Official record
Conditions
Pneumococcal Infection
Interventions
PPV23
Biological
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
19 Years to 65 Years
Enrollment
124 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 6, 2015 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional

APC-231 Once a Day (QD) for 7 Days vs. Penicillin Taken Four Times a Day (QID) in Pediatric Patients With Strep Throat

NCT00100126
View directory record Official record
Conditions
Pharyngitis
Interventions
Amoxicillin Pulsatile Release Multiparticluate Sprinkle
Drug
Lead sponsor
Advancis Pharmaceutical Corporation
Industry
Eligibility
6 Months to 12 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
Simpsonville, South Carolina • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 24, 2006 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Results available

Retapamulin Versus Linezolid in the Treatment of SITL and Impetigo Due to MRSA

NCT00852540
View directory record Official record
Conditions
Skin Infections, Bacterial
Interventions
Retpamulin Ointment, 1%, Linezolid
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
2 Months and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
53
States / cities
Anniston, Alabama • Birmingham, Alabama • Bentonville, Arkansas + 46 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2017 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)

NCT03480763
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™, PNEUMOVAX™23
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
652 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
15
States / cities
Chandler, Arizona • Phoenix, Arizona • Spring Valley, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)

NCT03692871
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
V114, Prevnar 13™
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
42 Days to 90 Days
Enrollment
2,409 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
22
States / cities
Downey, California • Huntington Beach, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Sep 28, 2026, 9:53 PM EDT
Completed Phase 3 Interventional

APC-111 MP Tablet Once a Day vs.Penicillin VK Four Times a Day Both for 10 Days in Patients With Strep Throat

NCT00242281
View directory record Official record
Conditions
Sore Throat, Pharyngitis, Tonsillitis
Interventions
APC-111 MP Tablet, 775 mg
Drug
Lead sponsor
Advancis Pharmaceutical Corporation
Industry
Eligibility
12 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
35
States / cities
Birmingham, Alabama • Tallassee, Alabama • Phoenix, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2006 · Synced Sep 28, 2026, 9:53 PM EDT